130 related articles for article (PubMed ID: 6641616)
1. [Effects of gamma-vinyl GABA per os in 5 cases of hebephreno-catatonic schizophrenia].
Lambert PA; Chabannnes JP; Cantiniaux P; Schechter PJ; Tell GP
Encephale; 1983; 9(2):145-9. PubMed ID: 6641616
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic trial of gamma-vinyl GABA, an inhibitor of GABA transaminase, in tardive dyskinesias induced by neuroleptics].
Lambert PA; Cantiniaux P; Chabannes JP; Tell GP; Schechter PJ; Koch-Weser J
Encephale; 1982; 8(3):371-6. PubMed ID: 6137357
[TBL] [Abstract][Full Text] [Related]
3. [Gamma-vinyl GABA and tardive dyskinesia: a single-blind study versus placebo].
Danion JM; Singer L; Tell G; Schechter P
Ann Med Psychol (Paris); 1984 Jan; 142(1):101-10. PubMed ID: 6476669
[No Abstract] [Full Text] [Related]
4. Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats.
Engelborghs S; Pickut BA; D'Hooge R; Wiechert P; Haegele K; De Deyn PP
Arzneimittelforschung; 1998 Jul; 48(7):713-6. PubMed ID: 9706369
[TBL] [Abstract][Full Text] [Related]
5. [Gamma-vinyl-GABA: the first trials in Italy].
de Romanis F; Sopranzi N
Clin Ter; 1993 Feb; 142(2):145-54. PubMed ID: 8472529
[TBL] [Abstract][Full Text] [Related]
6. Effect of gamma-vinyl GABA alone or associated with diazepam on a conflict test in the rat.
Huot S; Robin M; Palfreyman MG
Adv Biochem Psychopharmacol; 1981; 29():45-52. PubMed ID: 7257938
[No Abstract] [Full Text] [Related]
7. Schizophrenia with prominent catatonic features ('catatonic schizophrenia'): I. Demographic and clinical correlates in the chronic phase.
Ungvari GS; Leung SK; Ng FS; Cheung HK; Leung T
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):27-38. PubMed ID: 15610942
[TBL] [Abstract][Full Text] [Related]
8. Catatonic syndrome: importance of detection and treatment with lorazepam.
Seethalakshmi R; Dhavale S; Suggu K; Dewan M
Ann Clin Psychiatry; 2008; 20(1):5-8. PubMed ID: 18297580
[TBL] [Abstract][Full Text] [Related]
9. New antiepileptic drugs.
Richens A
Br J Hosp Med; 1990 Oct; 44(4):241. PubMed ID: 2249092
[No Abstract] [Full Text] [Related]
10. Evoked potential monitoring of vigabatrin patients.
Hammond EJ; Rangel RJ; Wilder BJ
Br J Clin Pract Suppl; 1988 Mar; 61():16-23. PubMed ID: 3145771
[No Abstract] [Full Text] [Related]
11. Vigabatrin: a new antiepileptic medication.
Mumford J; Dulac O
J Child Neurol; 1991; Suppl 2():S3-6. PubMed ID: 1940121
[No Abstract] [Full Text] [Related]
12. [Treatment of schizophrenic psychoses with Lyorodin].
Schulz HD; Kluge HH; Korda W; Kube B
Psychiatr Neurol Med Psychol (Leipz); 1977 Jun; 29(6):360-6. PubMed ID: 918199
[TBL] [Abstract][Full Text] [Related]
13. Adjusting the frequency of continuation and maintenance electroconvulsive therapy to prevent relapse of catatonic schizophrenia in middle-aged and elderly patients who are relapse-prone.
Suzuki K; Awata S; Takano T; Ebina Y; Shindo T; Harada N; Matsuoka H
Psychiatry Clin Neurosci; 2006 Aug; 60(4):486-92. PubMed ID: 16884452
[TBL] [Abstract][Full Text] [Related]
14. [Lithium in the treatment of periodically occurring catatonic arousal states in schizophrenic patients].
Weizsäcker M; Wöller W; Tegeler J
Nervenarzt; 1984 Jul; 55(7):382-4. PubMed ID: 6147768
[No Abstract] [Full Text] [Related]
15. [Report on the clinical testing of the delayed-action form of the neuroleptic agent moperone hydrochloride in 20 chronic psychotic patients].
Lydecken K
Schweiz Arch Neurol Neurochir Psychiatr; 1977; 120(1):75-82. PubMed ID: 323966
[TBL] [Abstract][Full Text] [Related]
16. [Exacerbation of catatonic symptoms in neuroleptic therapy].
Bräunig P; Krüger S; Höffler J
Nervenarzt; 1995 May; 66(5):379-82. PubMed ID: 7609820
[TBL] [Abstract][Full Text] [Related]
17. Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
Ungvari GS
Neuropsychopharmacol Hung; 2010 Dec; 12(4):463-7. PubMed ID: 21220791
[TBL] [Abstract][Full Text] [Related]
18. Schizophrenia with prominent catatonic features ('catatonic schizophrenia'). II. Factor analysis of the catatonic syndrome.
Ungvari GS; Goggins W; Leung SK; Gerevich J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):462-8. PubMed ID: 17188791
[TBL] [Abstract][Full Text] [Related]
19. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.
Duboc A; Hanoteau N; Simonutti M; Rudolf G; Nehlig A; Sahel JA; Picaud S
Ann Neurol; 2004 May; 55(5):695-705. PubMed ID: 15122710
[TBL] [Abstract][Full Text] [Related]
20. Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia.
Huang TL
Psychiatry Clin Neurosci; 2005 Feb; 59(1):52-5. PubMed ID: 15679540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
